NuCana plc
Research NuCana plc (NCNA) on Bullrun: market cap USD 6.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNCNA
- ExchangeNASDAQ
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.58M
- Financial periodQ1 2026
- Net income-USD 30.75M
- Free cash flow-USD 3.26M
Valuation Snapshot
latest market cap is USD 6.58M.
About NuCana plc
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells.
Frequently asked questions
What is NuCana plc's market cap?
NuCana plc's market capitalization is USD 6.58M.
What does NuCana plc do?
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.